Tagged: cancer-research
5 results
Laura E. Benjamin
Laura E. Benjamin is the CEO and President of Myris Therapeutics, a Pittsburgh-based biotech building ultra-high DAR antibody-drug conjugates that fuse polymer chemistry with cancer biologics. A molecular biologist by training, she has moved from Harvard pathology labs to Eli Lilly oncology leadership to two CEO chairs - most recently steering OncXerna through more than $100 million in clinical-stage financing before taking the helm at Myris in 2024.
Sean McCarthy
Sean McCarthy is the chairman, president and CEO of CytomX Therapeutics, a clinical-stage biopharma in South San Francisco building 'Probody' conditionally activated antibodies that switch on inside the tumor and stay quiet everywhere else. An Oxford-trained cancer biologist turned operator, he has run CytomX since 2011, taking it from a venture-backed startup to a Nasdaq-listed company with partnerships across Bristol Myers Squibb, AbbVie, Amgen, Astellas, Moderna and Regeneron.
Andrew Quong
Andrew Quong is President and CEO of InterVenn Biosciences, a South San Francisco-based precision diagnostics company unlocking the human glycoproteome through AI-powered platforms. With a PhD in Physics and over 30 years spanning national laboratories, academia, and biotech, Quong bridges the physical and computational sciences with clinical medicine. He led InterVenn's development of GlycoKnow Ovarian, a non-invasive blood-based liquid biopsy test for distinguishing ovarian cancer from benign masses, and has steered the company through key commercialization milestones including a $201M Series C raise in 2021.
Jorge Dimartino
Jorge F. DiMartino, M.D., Ph.D., is Chief Medical Officer and Executive Vice President of Clinical and Translational Development at Plexium, a San Diego-based biotech pioneering targeted protein degradation. A physician-scientist trained in genetics, immunology, and pediatric oncology across UC Berkeley, Cornell, UC San Diego, and Stanford, DiMartino has spent over two decades advancing cancer drugs from bench to bedside. His fingerprints are on three now-marketed therapies: vismodegib, venetoclax, and enasidenib - each a breakthrough in its own right. At Plexium, he oversees clinical programs targeting SMARCA2, IKZF2, CDK2, and CRAF using the company's DELTA Discovery platform, a novel approach to degrading proteins previously considered undruggable.
Mark Lee
Mark Lee, MD, PhD is the CEO and Co-Founder of N-Power Medicine, a Redwood City-based company reinventing how oncology clinical trials reach patients. A medical oncologist and scientist trained at Stanford and Harvard, Lee has spent his career at the frontier of personalized medicine - from developing Oncotype DX diagnostics at Genomic Health, to helping build early cancer detection at GRAIL, to leading personalized healthcare at Genentech/Roche. In 2021, he co-founded N-Power Medicine to embed research infrastructure directly into community oncology clinics, combining AI, embedded staff, and real-time registries to dramatically expand clinical trial access. After raising a $72M Series B led by Merck's Global Health Innovation Fund, N-Power acquired Syapse in late 2024 to build the largest community-based prospective clinical research network in oncology.